BI 2536 Second Line Monotherapy in SCLC
Public ClinicalTrials.gov record NCT00412880. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer
Study identification
- NCT ID
- NCT00412880
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- BI 2536 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 13, 2007
- Primary completion
- Jun 29, 2008
- Completion
- Jun 29, 2008
- Last update posted
- Jun 21, 2022
2007 – 2008
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1216.11.007 Boehringer Ingelheim Investigational Site | Fayetteville | Arkansas | — | — |
| 1216.11.003 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1216.11.006 Boehringer Ingelheim Investigational Site | Evanston | Illinois | — | — |
| 1216.11.002 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1216.11.005 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1216.11.001 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 1216.11.011 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1216.11.010 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1216.11.012 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00412880, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2022 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00412880 live on ClinicalTrials.gov.